SS-31 ยท Mitochondria-Targeted Tetrapeptide ยท Protocol Guide

Elamipretide (SS-31): The Cardiolipin Stabilizer Guide

Elamipretide is a mitochondrial-targeted peptide with one of the strongest preclinical rationales in this category. In September 2025 the FDA granted it accelerated approval, as Forzinity, for Barth syndrome only; other Phase III trials have been mixed. This guide separates the science from the speculation.

FDA Status
Approved for Barth Syndrome Only (2025)
Pharmacy
Licensed U.S. 503A compounding pharmacy
Medical Service
Rx Peps Direct, clinician-supervised
Access
28 States + DC

Our promise: Elamipretide has the cleanest mitochondrial-targeting mechanism in this category and a mixed clinical trial record. Phase III in age-related macular degeneration and Barth syndrome have produced different signals. We do not gloss over either.

Dr. Jonathan Snipes, MDMedically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.
On this page

Section 01

What Elamipretide Actually Is

Elamipretide is a 4-amino-acid synthetic peptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) developed by the Szeto-Schiller lab at Cornell. Trade name Bendavia, research designation SS-31. It is the most-pharmacologically-elegant compound in the mitochondrial-support category: it selectively concentrates 1000-fold in the inner mitochondrial membrane and binds cardiolipin, a phospholipid critical to electron transport chain function.

Stealth BioTherapeutics pursued FDA approval through multiple Phase III programs. The Barth syndrome program (a rare cardiomyopathy with cardiolipin remodeling failure) led to FDA accelerated approval, as Forzinity, in September 2025. Age-related macular degeneration trials produced mixed results. The compound is mechanistically clean, but the clinical translation has been harder than the preclinical data suggested.

4

Amino acids. One of the smallest mitochondria-targeted peptides in clinical use.

1000x

Concentration in inner mitochondrial membrane vs cytoplasm

Cardiolipin

Selective binding target. Critical phospholipid for electron transport.

Section 02

Who It Is Actually For

Profile

Documented mitochondrial dysfunction (post-viral, chronic illness)

Goal

Cardiolipin stabilization, ETC efficiency restoration

Fit

Strong Fit

Profile

Cardiometabolic optimization (40+, heart failure prevention)

Goal

Cardiac mitochondrial support

Fit

Adjunct Use

Profile

Longevity biohacker with mitochondrial focus

Goal

Stack with NAD+ and MOTS-c for comprehensive mitochondrial support

Fit

Speculative

Profile

Suspected Barth syndrome or rare mitochondrial disease

Goal

Cardiolipin remodeling defect treatment

Fit

Specialist Coordination

Profile

Active cancer (cardiolipin and mitochondrial biogenesis)

Goal

Mitochondrial support may benefit malignant cells

Fit

Clinician Decision Only

Section 03

How It Works

Elamipretide carries a 3-plus charge under physiological conditions and is electrostatically attracted to the negatively charged inner mitochondrial membrane. Once there, it binds cardiolipin and stabilizes the phospholipid environment around electron transport chain complexes. The downstream effects: improved ETC supercomplex assembly, reduced electron leak (less reactive oxygen species generation), and preserved ATP production.

Section 04

Realistic Expectations

Wk 1-2

No Acute Signal Expected

Elamipretide does not produce a next-day subjective effect. The compound operates at the mitochondrial membrane level and effects accumulate over weeks.

Wk 4-8

Cumulative Mitochondrial Effect

Patients with documented mitochondrial dysfunction may begin to notice improved exercise tolerance, reduced post-exertional malaise, and cognitive clarity. Healthy adults may notice nothing during this window.

Mo 3-6

Full Protocol Effect

Phase III trials assessed effect at 6-month endpoints. The most positive signals appeared in this window for the patient populations who responded. Non-response is common.

Section 05

Dosing Protocol

Context

Rx Peps Direct Standard

Dose

5 mg (33 units) subcutaneous

Frequency

Once daily, Monday to Friday

Evidence Basis

Clinical Practice

Context

Forzinity, FDA-approved for Barth syndrome

Dose

40 mg subcutaneous (specific disease state)

Frequency

Once daily

Evidence Basis

FDA Approved

Context

Phase II Macular Degeneration

Dose

40 mg

Frequency

Daily, 24-week course

Evidence Basis

Mixed Results

Subcutaneous injection into abdominal fat. Standard insulin syringe (28 to 31 gauge, 6 to 8 mm needle). Morning timing is preferred to align with daily energy demand. The clinical trial doses are substantially higher than the Rx Peps Direct protocol because they targeted specific severe disease states.

Side Effects and How to Manage Them

Elamipretide (SS-31) has the most documented clinical safety dataset of any mitochondria-targeted peptide because it went through late-stage FDA trials and, for Barth syndrome, FDA approval. Its Phase 3 SPARCL trial for heart failure and the Barth syndrome program produced well-characterized side effect frequencies. These are not estimated from community reports.

Side Effect

Injection site pain, redness, or swelling

Frequency

Common (25-30% in clinical trials)

When

At each injection

Mitigation

Documented in Phase 3 clinical trial. Rotate sites. Use 28 to 31 gauge needle. Allow vial to warm to room temperature

Side Effect

Mild nausea

Frequency

Uncommon (5-10%)

When

First week

Mitigation

Usually dose-related. Reduce dose for 3 days and re-escalate. Take with adequate hydration

Side Effect

Fatigue

Frequency

Uncommon (<10%)

When

First 1 to 2 weeks

Mitigation

Adaptation phase. Monitor for persistent fatigue beyond week 2, which warrants provider contact

Weekly Self-Monitoring Protocol

Elamipretide's clinical targets are mitochondrial function and energy production, tracked subjectively over time.

Metric

Energy / fatigue (0 to 10)

Frequency

Daily

Tool

Phone note

Signal to Report

No improvement by day 14 (discuss dose escalation)

Metric

Exercise tolerance (subjective 0 to 10)

Frequency

Weekly

Tool

Training log or phone note

Signal to Report

No improvement at week 4 at full dose

Metric

Injection site appearance

Frequency

Each injection

Tool

Visual inspection

Signal to Report

Induration, bruising, or lump lasting more than 48 hours

Metric

Subjective cognitive clarity (0 to 10)

Frequency

Daily, same time

Tool

Phone note

Signal to Report

Worsening clarity after week 2 (contact provider)

Section 06

Ready to Inject

0

Reconstitution steps required

503A

Licensed 503A pharmacy, clinician-supervised

Overnight

FedEx shipping in a reusable cooled travel case

Section 07

Stacking

Pairs Well With

  • NAD+ injectable

    Different layer of the mitochondrial system (redox cofactor). Complementary to elamipretide's membrane stabilization.

  • MOTS-c

    AMPK activation. Different mechanism, complementary mitochondrial support.

  • Coenzyme Q10 (oral)

    Native electron carrier. The full mitochondrial-support stack often includes CoQ10 alongside elamipretide.

  • Methylene blue (low-dose)

    Electron carrier bypass. Some practitioners combine these for severe mitochondrial dysfunction.

Approach With Caution

  • Active cancer

    Mitochondrial support can benefit malignant cells. Oncologist clearance required.

  • Pregnancy / lactation

    No safety data. Avoid.

  • Severe renal impairment

    Elamipretide is renally cleared. Clinician oversight on dose required.

  • Self-titration above prescribed dose

    Phase III trials and the FDA-approved Barth syndrome product use much higher doses for a specific severe disease. Higher does not mean better, and compounded SS-31 is not FDA approved for any use.

Section 08

Pricing

Who You Pay, and What For

Pharmacy: Medication

$100 per 75 mg vial. Compounded and shipped by a licensed U.S. 503A compounding pharmacy.

Medical Service: Clinician Consultation

$39 medical review. Intake consultation, protocol design, prescription writing, and follow-up. Billed by Rx Peps Direct.

Section 10

Community Q&A

SS-31 and Elamipretide are the same?

Yes. SS-31 is the Szeto-Schiller research designation. Elamipretide is the international nonproprietary name. Bendavia was an earlier trade name. Same molecule.

Do I need this in addition to NAD+ and MOTS-c?

Mechanism is different. Elamipretide stabilizes the inner mitochondrial membrane. NAD+ provides redox cofactor. MOTS-c activates AMPK. They target different layers of the same system. Most longevity-focused patients pick one or two rather than stacking all three.

Will my insurance cover this?

No. Compounded medications are typically not covered by insurance. You pay the pharmacy directly for the medication and pay Rx Peps Direct directly for the medical review.

Does the FDA-approved version change access to compounded SS-31?

Forzinity was approved in September 2025 for Barth syndrome only. When a finished form gains FDA approval, compounding access for the same molecule can narrow under FDA policy. Rx Peps Direct will communicate any access changes to active patients well in advance.

What if the pharmacy is out of stock?

Your Rx Peps Direct clinician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.

Section 11

The Rx Peps Direct Model

Pharmacy: Licensed U.S. 503A

The pharmacy compounds your elamipretide under a patient-specific prescription, USP <797> sterile compounding standards, and federal 503A oversight.

Medical Service: Rx Peps Direct Clinicians

A licensed clinician reviews your history, screens for contraindications, designs the protocol, and writes the prescription.

Transparent Safety Communication

The guide flags the mixed Phase III track record, the cancer contraindication, and what the 2025 Barth syndrome approval does and does not cover. We do not hide limitations.

Legal Access in 28 States + DC

Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a prescription.

References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. PMID: 24446857
  2. Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021. PMID: 33564154
  3. Mischley LK, Shankland E, Liu SZ, et al. ATP and NAD+ Deficiency in Parkinson's Disease. Nutrients. 2023. PMID: 37049533

Related protocol guides

Other protocols in the same clinical territory. Each guide is co-bylined by a licensed Rx Peps Direct prescriber.